NCT03770468

Molecular Genetic, Host-derived and Clinical Determinants of Long-term Survival in Glioblastoma

Completed Last updated 8 March 2024

What this trial tests

trial testing Blood drawl in Glioblastoma in 599 participants. Completed in 18 August 2023.

Timeline

5 July 2015

Primary endpoint
18 August 2023

18 August 2023

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	599
Start date	5 July 2015
Primary completion	18 August 2023
Estimated completion	18 August 2023
Sites	27 locations across France, Italy, Netherlands, Greece, Belgium, Austria, Germany, Switzerland

Drugs / interventions tested

• Blood drawl

Conditions studied

• Glioblastoma — all drugs for Glioblastoma →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

18 and older, any sex, with Glioblastoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This pro - and retrospective multicenter clinical epidemiological study studies the molecular genetic, host-derived and clinical determinants of glioblastoma patients with an overall survival of more than 5 years. The different research focusses are:

* Identification of clinical parameters and patient characteristics / host-related factors in long-term survivors (Focus 1)
* Identification of molecular tumor characteristics in long-term survivors (Focus 2)
* Assessment of therapy-related parameters, including neuro-toxicity (Focus 3)
* Immunological studies (Focus 4)

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

1. microRNA-based diagnostic and therapeutic applications in cancer medicine.
   Sempere LF, Azmi AS, Moore A. · · 2021 · cited 97× · PMID 33998154 · DOI 10.1002/wrna.1662
2. Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
   Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027
3. Cancer-associated fibroblasts in pancreatic cancer: new subtypes, new markers, new targets.
   Menezes S, Okail MH, Jalil SMA, Kocher HM, et al · · 2022 · cited 51× · PMID 35533046 · DOI 10.1002/path.5926
4. Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.
   Seyhan AA. · · 2024 · cited 44× · PMID 39063215 · DOI 10.3390/ijms25147974
5. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.
   Conley BA, Staudt L, Takebe N, Wheeler DA, et al · · 2021 · cited 22× · PMID 32339229 · DOI 10.1093/jnci/djaa061
6. Glioblastoma: Emerging Treatments and Novel Trial Designs.
   Di Nunno V, Franceschi E, Tosoni A, Gatto L, et al · · 2021 · cited 18× · PMID 34359651 · DOI 10.3390/cancers13153750
7. Dynamic Intercell Communication between Glioblastoma and Microenvironment through Extracellular Vesicles.
   Krapež G, Kouter K, Jovčevska I, Videtič Paska A. · · 2022 · cited 8× · PMID 35052830 · DOI 10.3390/biomedicines10010151